中国·永兴集团(yx5978)有限公司-官方网站

On August 26, 2026, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™, SSE: 688016) announced the interim results of Endovastec™ and its subsidiaries (the Company) for the six months ended June 30, 2026 (the Reporting Period). During the Reporting Period, the Company achieved revenue of RMB 794 million, with a net profit attributable to shareholders of listed companies of RMB 322 million and basic earnings per share of RMB 2.67. The Company expects to distribute total cash dividends of RMB 157 million (tax inclusive), representing a cash dividend of RMB 13 per 10 shares (tax inclusive).

Accelerating Product Innovation and Clinical Translation in Global Markets

The Company remains focused on aortic, peripheral vascular, and tumor intervention, adhering to a patient and clinical needs-oriented approach and committed to building more comprehensive total disease solutions. Since the beginning of 2026, the Company has accelerated the development of innovative products and the translation of clinical achievements in global markets. Significant progress has been made across its various product pipelines, with multiple new products receiving marketing approval in China, continued breakthroughs in overseas product registration and clinical use of key products, and steady progress in products under development.

In the field of aortic intervention, Hector™ Multi-Branch Thoracic Stent Graft System (recognized by NMPA as an innovative medical device）has successfully initiated pre-market clinical trials in China and received the U.S. FDA Breakthrough Device Designation, its custom-made products have been clinically applied in multiple countries across Europe, Africa, Southeast Asia, and Latin America. Cratos™ Branched Aortic Stent Graft System has progressed smoothly in post-market clinical use in China, while its CE MDR certification is currently under regulatory review, its custom-made products have been clinically applied in multiple countries across Europe, Asia, and Africa. Talos™ Thoracic Stent Graft System (recognized by NMPA as an innovative medical device）obtained CE MDR certification and has been clinically used in multiple countries across Europe, Latin America, and Southeast Asia. Zelus™ Thoracoabdominal Aortic Stent Graft System (Custom-Made) obtained a custom-made device filing certificate in China, completed the submission of its application for an EU custom-made device certificate, and has completed its first clinical uses in China and Europe. Aorfix™ AAA Endovascular Stent Graft with IntelliFlex™ Low Profile Delivery System has been granted access to the NMPA “Green Channel” for Innovative Medical Devices and completed its first clinical use in Macao, China. Aegis™ II Abdominal Aortic Stent Graft System is currently under registration review in China. Meridian™ Fenestrated Altura™ Endograft System is currently under CE MDR regulatory review. Metis™ Iliac Branched Stent Graft System is expected to enter pre-market clinical trials in China.

In the field of peripheral arterial intervention, HawkMaster™ Detachable Fibered Embolization Coils received marketing approval in China. SunFlow™ Drug-Eluting Peripheral Vascular Stent System was granted access to the NMPA “Green Channel” for Innovative Medical Devices and has successfully initiated pre-market clinical trials in China. SunRiver™ BTK Drug-Coated Balloon Catheter is currently under registration review in China. HawkNest™ Fibered Embolization Coils has progressed well in post-market clinical use in China.

In the field of peripheral venous intervention, Fishhawk™ Mechanical Thrombectomy Catheter (recognized by NMPA as an innovative medical device）received marketing approval in China. SeaNet™ Embolic Protection Device is currently under registration review in China. Vflower™ Venous Stent System (recognized by NMPA as an innovative medical device）has progressed well in post-market clinical use and completed its first clinical use outside China. Vewatch™ Vena Cava Filter, Vepack™ Snare Retrieval Kit, and SeaDragon™ PTA Balloon Dilatation Catheter have all been advancing smoothly in post-market clinical use.

In the field of tumor intervention, FinderSphere™ Polyvinyl Alcohol Embolic Microspheres and TorqueFlex™ Peripheral Vascular Microcatheters received marketing approval in China. HepaFlow™ TIPS Stent Graft System (recognized by NMPA as an innovative medical device）is currently under registration review for CE MDR certification. FluentSphere™ Polyvinyl Alcohol Embolic Microspheres is currently under registration review in China.

Steady Global Expansion and Deepening Overseas Market Presence

While continuously strengthening product innovation and development, the Company remains firmly committed to its globalization strategy, strengthening its market presence in China while steadily expanding overseas and deepening its international business presence.

The Company currently has a total of 35 marketed products worldwide, including distributed products. Among its proprietary innovative products, 26 have received NMPA marketing approval, 6 have obtained CE certification, and 3 have received EU custom-made device certificates. Among its products already launched and under development, 11 have been recognized by NMPA as Innovative Medical Devices, and 1 has received the U.S. FDA Breakthrough Device Designation.

During the Reporting Period, the Company continued to deepen its market penetration in China by strengthening sales channel development, further expanding its market reach and enhancing the depth and breadth of product coverage. As of the end of the Reporting Period, the Company’s market coverage continued to expand, with its products available in more than 3,000 hospitals in China, covering all 31 provinces, autonomous regions, and municipalities, as well as the Hong Kong and Macao special administrative regions. Its market share in aortic intervention products continued to lead the Chinese market, while market coverage of peripheral vascular intervention products continued to increase.

For international business, the Company continued to strengthen the promotion of innovative products in overseas markets, actively deepening collaboration with leading regional partners worldwide, and advancing market access and commercialization of its key aortic and peripheral vascular intervention products across Europe, Latin America, the Middle East, and the Asia-Pacific region. During the Reporting Period, overseas sales revenue increased by more than 21% year-over-year, excluding the impact of foreign exchange rate fluctuations. The Company has obtained more than 120 product registrations overseas, with its business covering 50 countries and regions across Europe, Latin America, Asia, and Africa.

Commitment to High-Quality Development and Corporate Social Responsibility

The Company remains committed to high-quality and sustainable development and actively fulfills its corporate social responsibility. It has published its CSR Reports for six consecutive years and has received “A” ratings or above from multiple leading ESG rating agencies in China. For four consecutive years, the Company has carried out the “Endovastec Public Welfare Action” Relief Program for impoverished patients with aortic diseases, benefiting more than 140 patients to date.

During the Reporting Period, the Company successfully passed the 2025 review of its designation as a National Enterprise Technology Center and was named among the Top 100 Shanghai Specialized, Sophisticated, Distinctive and Innovative Enterprises by Brand Value in 2025. Cratos™ Branched Aortic Stent Graft System was included in the 15th batch of the Shanghai Recommended Catalog of Innovative Products.

“In the first half of 2026, amid changes and challenges in the industry environment, we remained committed to innovation-driven development and focused on clinical needs, while steadily strengthening our presence in China and expanding our global footprint. Every step forward reflects the dedication of our employees and the trust and support of our customers, partners, shareholders, and the broader community. Looking ahead, we will remain focused on advancing innovative total solutions for aortic, peripheral vascular, and tumor diseases, and steadily move toward our goal of becoming a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine,” said Qing Zhu, PhD, President of Endovastec™.

This article does not constitute any form of medical advice or product promotion. For any medical diagnostic issues, please be sure to consult qualified healthcare professionals.